Portfolio of Biotech Stocks: Second Portfolio

Here is a sample of 10 biotech stocks from the universe of biotechnology companies.


10 Biotech Stocks: Second Portfolio

Stock Returns & Price Chart

Symbol

Recent Prices &
Annualized Return

Audentes TherapeuticsBOLD
Aimmune TherapeuticsAIMT
AlkermesALKS
Ionis PharmaceuticalsIONS
Madrigal PharmaceuticalsMDCL
Neurocrine BiosciencesNBIX
RegenxbioRGNX
Sarepta TherapeuticsSRPT
Vanda PharmaceuticalsVNDA
Viking TherapueticsVKTX
Price data from Quandl as of most recent close.


10 Biotech Stocks: Second Portfolio

Stock Returns & Price Chart

Symbol

Recent Dividends

Audentes TherapeuticsBOLD
Aimmune TherapeuticsAIMT
AlkermesALKS
Ionis PharmaceuticalsIONS
Madrigal PharmaceuticalsMDCL
Neurocrine BiosciencesNBIX
RegenxbioRGNX
Sarepta TherapeuticsSRPT
Vanda PharmaceuticalsVNDA
Viking TherapueticsVKTX
Dividend chart data from Quandl as of today.


To inspect the performance of the Biotech Stocks: Second Portfolio portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.

The 5 stocks included in the portfolio computations are: ALKS, IONS, NBIX, SRPT and VNDA. The current value of the portfolio assumes that $2,000.00 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. The 5 stocks excluded from the portfolio computations because of insufficient price data are: BOLD, AIMT, MDCL, RGNX and VKTX.

The current value of a $10,000 investment is $130,069. The percent return is 1,200.69%. The annualized return is 29.25%.



Return Summary for Biotech Stocks: Second Portfolio
Start DateDec-31-2009
Start Investment$10,000.00
End DateDec-06-2019
Current Value of Investment$130,069.14
Total Return1,200.69%
Annualized Return29.25%
Min DateFeb-26-2010
Min Price$9,751.92
Max DateSep-28-2018
Max Price$149,664.36
# Values121
Number Returns7,260
Number Profitable Returns6,726
Percent Profitable Returns92.64%
Number Unprofitable Returns534
Percent Unprofitable Returns7.36%
Profitable to Unprofitable Returns Ratio12.60


NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.

Related Portfolios

Portfolio of Biotech Stock: First Portfolio

Portfolio of Biotech Stocks: Diabetes

Portfolio of Dividend-Paying Pharmaceutical Stocks

Portfolio of Stem Cell Stocks